What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer.
- Since April 2021 when she was hired as the company’s chief strategy officer, Miruna has helped spearhead a series of research collaborations focused on investigating racial disparities in cancer care and the drug development process, including partnerships with the University of Chicago
Read More
COTA
70% of US Oncologists Are Wrong About Clinical Trial Diversity
What You Should Know:
- COTA's study reveals that 70 percent of oncologists believe patient populations enrolled in clinical trials for cancer research are representatively diverse.
COTA, Inc., an oncology real-world data and analytics company, announced insights from a study of practicing oncologists that reveals 83 percent of oncologists surveyed believe real-world data is critical to accelerating the development of potentially life-saving cancer drugs and treatments. The study, which
Read More
U of Chicago Med & COTA to Address Racial Disparities in Cancer Using RWD
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer.
- Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur
Read More
COTA Lands $34M to Drive Innovation in Oncology Using Real-World Data
What You Should Know:
- COTA, Inc., a healthcare technology company that uses
real-world data to bring clarity to cancer care, has secured $34M in funding.
- Access to over one million patient data records and additional
funding support enhanced real-world data and analytics services in oncology.
COTA, Inc., a Boston, MA-based healthcare technology company that uses real-world data to bring clarity to cancer care, today announced it has raised $34 million in Series D funding led by
Read More
FDA Extends RCA With COTA to Explore COVID’s Effect on Cancer
What You Should Know:
- The FDA just extended its research collaboration
agreement (RCA) with COTA, specifically looking at how COVID-19 is affecting
cancer.
- With this expanded agreement, COTA and the FDA will use real-world data to explore the impact of COVID-19 and the pandemic on cancer treatment, with the opportunity to expand into other oncology questions in the future.
COTA, Inc., a healthcare technology
company that uses real-world data to bring clarity to cancer care,
Read More
Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform
What You Should Know:
- Mission Bio raises $70 million in Series C funding led by
Novo Growth to accelerate the development of cancer therapies with single-cell multi-omics.
- Mission Bio’s Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that drive disease to accelerate the development of novel treatments and save patient lives.
Mission Bio,
Inc., a South San Francisco,
Read More
2020 MedTech Breakthrough Award Winners Announced
What You Should Know:
- MedTech Breakthrough announces 2020 MedTech Breakthrough Award Winners that recognizes the top companies, people, platforms, and products in the health, fitness, and medical technology industries today.
- The 2020 MedTech Breakthrough Awards program is open to all individuals, companies, and organizations involved in producing digital health and medical technology products and services.
MedTech
Breakthrough, a market intelligence organization that recognizes
Read More
Cota Lands $40M to Accelerate Value-based Precision Medicine
Cota, a NYC-based healthcare data and analytics company bridging precision medicine to population health has raised $40 million in Series C funding led by QVIA and was contributed to by EW Healthcare Partners. Memorial Sloan Kettering Cancer Center also participated in the round, along with existing Cota investors which include, Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings.The funding will go towards rapidly scaling its
Read More
Cota Partners with Miami Cancer Institute to Fuel Personalized Cancer Treatment
Cota, a healthcare data and analytics company bridging precision medicine to population health has announced their latest collaboration with Baptist Health South Florida to advance cancer treatment and clinical research at the new Miami Cancer Institute (MCI). The partnership will further support the organization’s initiative of precision medicine, improve care delivery and ensure the most effective treatment for every type of cancer.MCI will leverage Cota’s Provider Solution to identify
Read More
Memorial Sloan Kettering, Cota Partner to Advance Personalized Cancer Treatment
In 2011, Cota, a healthcare data and analytics company bridging precision medicine and population health, was founded by doctors for doctors. Over the past six years, the start-up has moved beyond precision medicine as a goal to a reality, and just this past year, have secured a multi-year collaboration with Novartis towards breast cancer and recruited top thought leaders in the space, like former Deputy Chief Health Officer at IBM Watson, Dr. Andrew Norden.Today, Cota announced their latest
Read More
